Killers 2.0: NK cell therapies at the forefront of cancer control

Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells

(2019) Takahiro Kamiya et al.   JOURNAL OF CLINICAL INVESTIGATION

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

(2019) Laurent Gauthier et al.   CELL

Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL

(2018) Frank Vari et al.   BLOOD

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

(2018) Ye Li et al.   Cell Stem Cell

Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors

(2018) Tobias Speck et al.   CLINICAL CANCER RESEARCH

Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models

(2018) Bai Liu et al.   CYTOKINE

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Canonical TGF-β Signaling Pathway Represses Human NK Cell Metabolism

(2018) Vanessa Zaiatz-Bittencourt et al.   JOURNAL OF IMMUNOLOGY

CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape

(2018) David Pettitt et al.   MOLECULAR THERAPY

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

(2018) Qing Zhang et al.   NATURE IMMUNOLOGY

Complex role of NK cells in regulation of oncolytic virus–bortezomib therapy

(2018) Yangjin Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity

(2018) Lucas Ferrari de Andrade et al.   SCIENCE

Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned

(2018) Jeanette E. Boudreau et al.   TRENDS IN IMMUNOLOGY

NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia

(2018) Franco Locatelli et al.   TRENDS IN IMMUNOLOGY

High-Risk Leukemia: Past, Present, and Future Role of NK Cells

(2018) Melissa Mavers et al.   Journal of Immunology Research

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

(2018) Rohtesh S. Mehta et al.   Frontiers in Immunology

Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity

(2018) Lee-Hwa Tai et al.   OncoImmunology

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity

(2018) Amelia Roman Aguilera et al.   OncoImmunology

Natural Killer Cell IFNγ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery

(2018) Leonard Angka et al.   ANNALS OF SURGICAL ONCOLOGY

Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy

(2018) Elizabeth L. Siegler et al.   Cell Stem Cell

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

(2018) Joy Hsu et al.   JOURNAL OF CLINICAL INVESTIGATION

First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.

(2018) Neil Howard Segal et al.   JOURNAL OF CLINICAL ONCOLOGY

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines

(2018) Nadine van Montfoort et al.   CELL

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

(2018) Pascale André et al.   CELL

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

(2018) Jun Wang et al.   CELL

Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response

(2018) Assaf Marcus et al.   IMMUNITY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination

(2018) Marcus Ruscetti et al.   SCIENCE

PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients

(2018) Fernando Concha-Benavente et al.   Cancer Immunology Research

PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression

(2018) Francesca R. Mariotti et al.   OncoImmunology

The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction

(2018) Marisa Market et al.   Cancers

The Broad Spectrum of Human Natural Killer Cell Diversity

(2017) Aharon G. Freud et al.   IMMUNITY

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery

(2017) Leonard Angka et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression

(2017) Michal Šmahel   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization

(2017) Silvia Pesce et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

(2017) E Liu et al.   LEUKEMIA

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

(2017) Frederick L. Locke et al.   MOLECULAR THERAPY

Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers

(2017) Y Liu et al.   ONCOGENE

Cytokines in Cancer Immunotherapy

(2017) Thomas A. Waldmann   Cold Spring Harbor Perspectives in Biology

IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours

(2017) Hyungseok Seo et al.   Nature Communications

Endothelial cells express NKG2D ligands and desensitize antitumor NK responses

(2017) Thornton W Thompson et al.   eLife

NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

(2017) Almohanad A. Alkayyal et al.   Cancer Immunology Research

Generation of “Off-the-Shelf” Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells

(2017) Jieming Zeng et al.   Stem Cell Reports

Role of Distinct Natural Killer Cell Subsets in Anticancer Response

(2017) Helena Stabile et al.   Frontiers in Immunology

NK Cell Exhaustion

(2017) Jiacheng Bi et al.   Frontiers in Immunology

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance

(2017) Alessandra Zingoni et al.   Frontiers in Immunology

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

(2016) D. A. Vallera et al.   CLINICAL CANCER RESEARCH

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

(2016) M. Carlsten et al.   CLINICAL CANCER RESEARCH

Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy

(2016) Alessandra Zingoni et al.   CRITICAL REVIEWS IN IMMUNOLOGY

CIS is a potent checkpoint in NK cell–mediated tumor immunity

(2016) Rebecca B Delconte et al.   NATURE IMMUNOLOGY

Targeting natural killer cells in cancer immunotherapy

(2016) Camille Guillerey et al.   NATURE IMMUNOLOGY

Driving CAR T-cells forward

(2016) Hollie J. Jackson et al.   Nature Reviews Clinical Oncology

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

(2016) Sébastien Viel et al.   Science Signaling

PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma

(2016) Asma Beldi-Ferchiou et al.   Oncotarget

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

(2016) Peter S. Kim et al.   Oncotarget

A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

(2016) Xilin Chen et al.   Oncotarget

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway

(2016) Sébastien Viel et al.   Science Signaling

Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

(2016) L. Galluzzi et al.   Cancer Immunology Research

Features of Memory-Like and PD-1+ Human NK Cell Subsets

(2016) Mariella Della Chiesa et al.   Frontiers in Immunology

High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer

(2016) Cheng Sun et al.   OncoImmunology

Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma

(2016) Alejandra Leivas et al.   OncoImmunology

Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond

(2015) Stephen M. Ansell   AMERICAN JOURNAL OF HEMATOLOGY

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

(2015) D. M. Benson et al.   CLINICAL CANCER RESEARCH

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells

(2015) L. Ruggeri et al.   HAEMATOLOGICA

The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer

(2015) Zhenxin Wang et al.   IMMUNOLOGICAL INVESTIGATIONS

A bird's eye view of NK cell receptor interactions with their MHC class I ligands

(2015) Philippa M. Saunders et al.   IMMUNOLOGICAL REVIEWS

Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma

(2015) Liyun Xu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy

(2015) Katrin Töpfer et al.   JOURNAL OF IMMUNOLOGY

Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

(2015) Naoyuki Sakamoto et al.   Journal of Translational Medicine

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors

(2015) HIDEO KOMITA et al.   ONCOLOGY REPORTS

Invasive Surgery Impairs the Regulatory Function of Human CD56bright Natural Killer Cells in Response to Staphylococcus aureus. Suppression of Interferon-γ Synthesis

(2015) Renate Reinhardt et al.   PLoS One

A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection

(2015) W. Deng et al.   SCIENCE

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

DNAM-1: would the real natural killer cell please stand up!

(2015) Nicholas D. Huntington et al.   Oncotarget

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells

(2015) L. Ruggeri et al.   HAEMATOLOGICA

Improving the safety of cell therapy with the TK-suicide gene

(2015) Raffaella Greco et al.   Frontiers in Pharmacology

Human Leukocyte Antigen E Contributes to Protect Tumor Cells from Lysis by Natural Killer Cells

(2015) Elisa Lo Monaco et al.   NEOPLASIA

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

(2014) M. K. Gleason et al.   BLOOD

LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

(2014) F. Xu et al.   CANCER RESEARCH

Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor

(2014) D. Mittal et al.   CANCER RESEARCH

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

(2014) N. Korde et al.   HAEMATOLOGICA

Cytokine therapy reverses NK cell anergy in MHC-deficient tumors

(2014) Michele Ardolino et al.   JOURNAL OF CLINICAL INVESTIGATION

Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

(2014) Fiona Errington et al.   JOURNAL OF IMMUNOLOGY

Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease

(2014) Jiqing Zhang et al.   MOLECULAR THERAPY

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

(2014) Yu-Hwa Huang et al.   NATURE

Myxoma Virus Expressing a Fusion Protein of Interleukin-15 (IL15) and IL15 Receptor Alpha Has Enhanced Antitumor Activity

(2014) Vesna Tosic et al.   PLoS One

NK cell self tolerance, responsiveness and missing self recognition

(2014) Nataliya Shifrin et al.   SEMINARS IN IMMUNOLOGY

Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade

(2014) I. P. da Silva et al.   Cancer Immunology Research

Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition

(2013) Eric O. Long et al.   Annual Review of Immunology

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells

(2013) Rauf Bhat et al.   BMC CANCER

Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells

(2013) Daniel A. Vallera et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor  Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma

(2013) W. Xu et al.   CANCER RESEARCH

A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells

(2013) Y.-H. Chang et al.   CANCER RESEARCH

Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin

(2013) R. Remark et al.   CLINICAL CANCER RESEARCH

Perioperative Influenza Vaccination Reduces Postoperative Metastatic Disease by Reversing Surgery-Induced Dysfunction in Natural Killer Cells

(2013) L.-H. Tai et al.   CLINICAL CANCER RESEARCH

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

(2013) A. Wiernik et al.   CLINICAL CANCER RESEARCH

Treatment of patients with advanced cancer with the natural killer cell line NK-92

(2013) Torsten Tonn et al.   CYTOTHERAPY

Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3

(2013) C. Fionda et al.   JOURNAL OF IMMUNOLOGY

Myxoma Virus Infection Promotes NK Lysis of Malignant Gliomas In Vitro and In Vivo

(2013) Henry Ogbomo et al.   PLoS One

Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications

(2013) G. Chitadze et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy

(2013) David A. Knorr et al.   Stem Cells Translational Medicine

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

(2012) L. C. Ndhlovu et al.   BLOOD

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

(2012) N. Vey et al.   BLOOD

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

(2012) M. K. Gleason et al.   BLOOD

Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells

(2012) L.-H. Tai et al.   CANCER RESEARCH

Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma

(2012) S. Miyamoto et al.   CANCER RESEARCH

Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors

(2012) Jing Ni et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

(2012) M. K. Gleason et al.   MOLECULAR CANCER THERAPEUTICS

Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine

(2012) Chantal G Lemay et al.   MOLECULAR THERAPY

Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’

(2012) Aron M. Levin et al.   NATURE

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

(2012) Shigeki Chiba et al.   NATURE IMMUNOLOGY

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors

(2012) Christopher A Alvarez-Breckenridge et al.   NATURE MEDICINE

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

(2012) Cecele J. Denman et al.   PLoS One

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

(2011) A. Curti et al.   BLOOD

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

(2011) D. M. Benson et al.   BLOOD

DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction

(2011) M. Ardolino et al.   BLOOD

Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity

(2011) K B Stephenson et al.   CANCER GENE THERAPY

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

(2011) S. Platonova et al.   CANCER RESEARCH

Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression

(2011) M. R. Parkhurst et al.   CLINICAL CANCER RESEARCH

Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF

(2011) K-J Choi et al.   GENE THERAPY

HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression

(2011) Céline Bossard et al.   INTERNATIONAL JOURNAL OF CANCER

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

DNA Alkylating Therapy Induces Tumor Regression through an HMGB1-Mediated Activation of Innate Immunity

(2011) J. L. Guerriero et al.   JOURNAL OF IMMUNOLOGY

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

(2011) Nicolas F Delahaye et al.   NATURE MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes

(2011) M. Gooden et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer

(2010) Phonphimon Wongthida et al.   CANCER RESEARCH

Chemotherapy-Induced Genotoxic Stress Promotes Sensitivity to Natural Killer Cell Cytotoxicity by Enabling Missing-Self Recognition

(2010) J. H. Fine et al.   CANCER RESEARCH

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

(2010) Melissa A. Geller et al.   CYTOTHERAPY

Enhancement of NK cell antitumor responses using an oncolytic parvovirus

(2010) Rauf Bhat et al.   INTERNATIONAL JOURNAL OF CANCER

NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia

(2010) Jeffrey E. Rubnitz et al.   JOURNAL OF CLINICAL ONCOLOGY

T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells

(2010) Rosemarie H. DeKruyff et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity

(2009) P. S. Woll et al.   BLOOD

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Maturation of mouse NK cells is a 4-stage developmental program

(2009) L. Chiossone et al.   BLOOD

Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines

(2009) Javier G. Casado et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma

(2009) J. M. Venstrom et al.   CLINICAL CANCER RESEARCH

Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation

(2009) C. Fionda et al.   JOURNAL OF IMMUNOLOGY

Targeting the Intratumoral Dendritic Cells by the Oncolytic Adenoviral Vaccine Expressing RANTES Elicits Potent Antitumor Immunity

(2009) Natalia Lapteva et al.   JOURNAL OF IMMUNOTHERAPY

Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase

(2009) M. Jarahian et al.   JOURNAL OF VIROLOGY

Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells

(2009) Henry Ogbomo et al.   MEDICAL MICROBIOLOGY AND IMMUNOLOGY

Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity

(2009) Jeanette E Boudreau et al.   MOLECULAR THERAPY

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

(2008) A. Soriani et al.   BLOOD

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells

(2008) Paolo Carrega et al.   CANCER

Accelerated tumor growth in mice deficient in DNAM-1 receptor

(2008) Akiko Iguchi-Manaka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Exponential Enhancement of Oncolytic Vesicular Stomatitis Virus Potency by Vector-mediated Suppression of Inflammatory Responses In Vivo

(2007) Jennifer Altomonte et al.   MOLECULAR THERAPY